Bile acid metabolism and signaling, the microbiota, and metabolic disease DOI Creative Commons
Jingwei Cai, Bipin Rimal, Changtao Jiang

и другие.

Pharmacology & Therapeutics, Год журнала: 2022, Номер 237, С. 108238 - 108238

Опубликована: Июль 2, 2022

Язык: Английский

Gut microbiota in human metabolic health and disease DOI
Yong Fan, Oluf Pedersen

Nature Reviews Microbiology, Год журнала: 2020, Номер 19(1), С. 55 - 71

Опубликована: Сен. 4, 2020

Язык: Английский

Процитировано

3302

Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3 DOI Creative Commons
Francesco Beghini, Lauren J. McIver, Aitor Blanco‐Míguez

и другие.

eLife, Год журнала: 2021, Номер 10

Опубликована: Май 4, 2021

Culture-independent analyses of microbial communities have progressed dramatically in the last decade, particularly due to advances methods for biological profiling via shotgun metagenomics. Opportunities improvement continue accelerate, with greater access multi-omics, reference genomes, and strain-level diversity. To leverage these, we present bioBakery 3, a set integrated, improved taxonomic, strain-level, functional, phylogenetic metagenomes newly developed build on largest sequences now available. Compared current alternatives, MetaPhlAn 3 increases accuracy taxonomic profiling, HUMAnN improves that functional potential activity. These detected novel disease-microbiome links applications CRC (1262 metagenomes) IBD (1635 817 metatranscriptomes). Strain-level an additional 4077 StrainPhlAn PanPhlAn unraveled structure common gut microbe Ruminococcus bromii , previously described by only 15 isolate genomes. With open-source implementations cloud-deployable reproducible workflows, platform can help researchers deepen resolution, scale, multi-omic community studies.

Язык: Английский

Процитировано

1427

Role of gut microbiota in type 2 diabetes pathophysiology DOI Creative Commons
Manoj Gurung, Zhipeng Li,

Hannah You

и другие.

EBioMedicine, Год журнала: 2020, Номер 51, С. 102590 - 102590

Опубликована: Янв. 1, 2020

A substantial body of literature has provided evidence for the role gut microbiota in metabolic diseases including type 2 diabetes. However, reports vary regarding association particular taxonomic groups with disease. In this systematic review, we focused on potential different bacterial taxa affecting We have summarized from 42 human studies reporting microbial associations disease, and identified supporting preclinical or clinical trials using treatments probiotics. Among commonly reported findings, genera Bifidobacterium, Bacteroides, Faecalibacterium, Akkermansia Roseburia were negatively associated T2D, while Ruminococcus, Fusobacterium, Blautia positively T2D. also discussed molecular mechanisms effects onset progression

Язык: Английский

Процитировано

1378

The pros, cons, and many unknowns of probiotics DOI
Jotham Suez, Niv Zmora, Eran Segal

и другие.

Nature Medicine, Год журнала: 2019, Номер 25(5), С. 716 - 729

Опубликована: Май 1, 2019

Язык: Английский

Процитировано

1048

Interaction between drugs and the gut microbiome DOI Creative Commons
Rinse K. Weersma, Alexandra Zhernakova, Jingyuan Fu

и другие.

Gut, Год журнала: 2020, Номер 69(8), С. 1510 - 1519

Опубликована: Май 14, 2020

The human gut microbiome is a complex ecosystem that can mediate the interaction of host with their environment. between microbes and commonly used non-antibiotic drugs bidirectional: composition be influenced by drugs, but, vice versa, also influence an individual's response to drug enzymatically transforming drug's structure altering its bioavailability, bioactivity or toxicity (pharmacomicrobiomics). indirectly impact immunotherapy in cancer treatment. In this review we discuss bidirectional interactions describe changes microbiota induced potential clinical consequences summarise how impacts effectiveness role immunotherapy. Understanding metabolises reduces treatment efficacy will unlock possibility modulating improve

Язык: Английский

Процитировано

712

Benefits of Metformin in Attenuating the Hallmarks of Aging DOI Creative Commons
Ameya Kulkarni, Sriram Gubbi, Nir Barzilai

и другие.

Cell Metabolism, Год журнала: 2020, Номер 32(1), С. 15 - 30

Опубликована: Апрель 24, 2020

Язык: Английский

Процитировано

561

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus DOI
Marc Foretz, Bruno Guigas, Benoı̂t Viollet

и другие.

Nature Reviews Endocrinology, Год журнала: 2019, Номер 15(10), С. 569 - 589

Опубликована: Авг. 22, 2019

Язык: Английский

Процитировано

532

Metformin and Its Benefits for Various Diseases DOI Creative Commons

Ziquan Lv,

Yajie Guo

Frontiers in Endocrinology, Год журнала: 2020, Номер 11

Опубликована: Апрель 16, 2020

Metformin is a widely used biguanide drug due to its safety and low cost. It has been for over 60 years treat type 2 diabetes at the early stages because of outstanding ability decrease plasma glucose levels. Over time, different uses metformin were discovered, benefits various diseases even aging verified. These include cancers (e.g., breast cancer, endometrial bone colorectal melanoma), obesity, liver diseases, cardiovascular disease, renal diseases. exerts effects through signaling pathways. However, underlying mechanisms these remain be elucidated. The aim this review provide brief summary discuss possible mechanisms.

Язык: Английский

Процитировано

428

Gut-liver axis: Pathophysiological concepts and clinical implications DOI Creative Commons
Herbert Tilg, Timon E. Adolph, Michael Trauner

и другие.

Cell Metabolism, Год журнала: 2022, Номер 34(11), С. 1700 - 1718

Опубликована: Окт. 7, 2022

Язык: Английский

Процитировано

382

The Gut Microbiota in Prediabetes and Diabetes: A Population-Based Cross-Sectional Study DOI Creative Commons
Hao Wu, Valentina Tremaroli, Caroline Schmidt

и другие.

Cell Metabolism, Год журнала: 2020, Номер 32(3), С. 379 - 390.e3

Опубликована: Июль 10, 2020

Язык: Английский

Процитировано

373